More than 24 million people are un- or under-screened for cervical cancer. At-home sample collection is planned for 2027.
Quest Diagnostics and Waters Corporation plan to expand access to the Onclarity Self-Collection Kit for cervical cancer screening in 2027. The kit, used with the BD Onclarity HPV Assay, allows at-home sample collection and provides comprehensive genotyping. Quest, serving half of U.S. physicians, will distribute the kit through its clinician, health plan, and consumer channels.
How this was made
The 30-second read
Why it matters
The partnership creates a new distribution channel for both companies, potentially adding incremental revenue but with a multi‑year horizon.
Market read
Introduces a novel at‑home cervical cancer screening product, relevant for healthcare investors and diagnostics sector analysts.
What to watch
Regulatory approvals for self‑collection kits in other jurisdictions could affect long‑term growth.
Background
The article is a press release describing a new collaboration between Quest Diagnostics and Waters to bring an FDA‑approved at‑home HPV test to market.
Ticker impact
Quest Diagnostics announced a partnership with Waters to launch an at‑home HPV self‑collection kit, expanding its testing services starting in 2027.
likely modest upside as market prices in new revenue opportunity
The collaboration opens a new consumer channel for Quest, but rollout is years away and financial impact is uncertain.
Waters Corporation disclosed its first FDA‑cleared HPV self‑collection kit, partnering with Quest Diagnostics for distribution beginning in 2027.
likely modest upside as investors value the new product line
The product launch diversifies Waters' revenue streams, though commercial uptake will take time.
Market effects
Strengthens the diagnostics and women's health testing sector with at‑home capabilities.
U.S. healthcare market gains a new consumer‑focused screening option.
Potential model for other markets seeking at‑home HPV testing solutions.
Counterpoint
Revenue impact may be limited if insurance coverage for at‑home HPV testing remains low.
Key entities
- CompanyQuest Diagnostics
U.S. clinical laboratory services provider (ticker DGX).
- CompanyWaters Corporation
Life‑sciences and diagnostics company (ticker WAT).
